共 50 条
Allogeneic hematopoietic stem cell transplantation in a prior lung transplant recipient
被引:0
|作者:
Fujiwara, Yuki
[1
]
Matsuoka, Ken-ichi
[1
]
Iwamoto, Miki
[1
]
Sumii, Yuichi
[1
]
Abe, Masaya
[1
]
Mizuhara, Kentaro
[1
]
Urata, Tomohiro
[1
]
Saeki, Kyosuke
[1
]
Meguri, Yusuke
[1
]
Asada, Noboru
[1
]
Ennishi, Daisuke
[1
]
Nishimori, Hisakazu
[1
]
Fujii, Keiko
[1
]
Fujii, Nobuharu
[1
]
Sugita, Junichi
[2
]
Kobayashi, Hajime
[3
]
Oto, Takahiro
[4
]
Maeda, Yoshinobu
[1
]
机构:
[1] Okayama Univ Hosp, Dept Hematol & Oncol, Kita Ku, 2-5-1 Shikatacho, Okayama, Okayama 7008558, Japan
[2] Hokkaido Univ Hosp, Dept Hematol, Sapporo, Hokkaido, Japan
[3] Obihiro Kosei Hosp, Dept Hematol, Obihiro, Hokkaido, Japan
[4] Okayama Univ Hosp, Dept Organ Transplant Ctr, Okayama, Japan
基金:
日本学术振兴会;
关键词:
Myelodysplastic syndromes;
Lung transplant;
Allogeneic hematopoietic stem cell transplantation;
Transplant tolerance;
MYELOID NEOPLASMS;
CORD BLOOD;
RISK;
D O I:
10.1007/s12185-020-02967-x
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Hematological diseases after solid organ transplant (SOT) are an emerging issue as the number of long-term SOT survivors increases. Expertise in managing patients requiring allogeneic hematopoietic stem cell transplantation (HSCT) after SOT from independent donors is needed; however, clinical reports of HSCT after SOT are limited, and the feasibility and risk are not well understood. In particular, HSCT in prior lung transplant recipients is thought to be complicated as the lung is immunologically distinct and is constantly exposed to the surrounding environment. Herein, we describe a case of successful HSCT in a patient with myelodysplastic syndromes who had previously received a lung transplant from a deceased donor for bronchiolitis obliterans syndrome. Reports about cases of HSCT after lung transplant are quite rare; thus, we discuss the mechanisms of immune tolerance through the clinical course of our case. This case suggests that HSCT after SOT can be considered a therapeutic option in cases where the transplanted organ is functionally retained and the hematological disease is in remission.
引用
收藏
页码:871 / 877
页数:7
相关论文